{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen%2C+and+pelvis&page=2", "query": { "intervention": "CT chest, abdomen, and pelvis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen%2C+and+pelvis&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen%2C+and+pelvis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T16:17:27.570Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03574818", "title": "Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Lung Cancer" ], "interventions": [ { "name": "Necitumumab-Gemcitabine-Cisplatin", "type": "DRUG" }, { "name": "Evaluation to determine if patient is a candidate to proceeed with surgical resection or not", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-05-29", "completion_date": "2019-09-26", "has_results": true, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03574818" }, { "nct_id": "NCT06942104", "title": "Imaging of Solid Tumors Using 18F-TRX", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Carcinoma", "Castration-Resistant Prostate Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Glioma, Malignant" ], "interventions": [ { "name": "18F-TRX", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)/Computerized tomography (CT)", "type": "PROCEDURE" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "Blood Specimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-07-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942104" }, { "nct_id": "NCT07859800", "title": "Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Volunteer", "Malaria" ], "interventions": [ { "name": "18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "54 Years", "sex": "ALL", "summary": "18 Years to 54 Years" }, "enrollment_count": 45, "start_date": "2026-10-14", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07859800" }, { "nct_id": "NCT04634227", "title": "Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sarcoma", "Soft Tissue Sarcoma", "Unresectable Soft Tissue Sarcoma", "Metastatic Bone Tumor", "Bone Sarcoma" ], "interventions": [ { "name": "Ascorbate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-11-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634227" }, { "nct_id": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Chronic Lymphocytic Lymphoma", "B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "CT Scan chest/abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "18-FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-12-16", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599634" }, { "nct_id": "NCT06401330", "title": "A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Mixed Cell Type Kidney Wilms Tumor", "Stage II Mixed Cell Type Kidney Wilms Tumor", "Stage III Mixed Cell Type Kidney Wilms Tumor", "Stage IV Mixed Cell Type Kidney Wilms Tumor" ], "interventions": [ { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nephrectomy", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 1656, "start_date": "2025-04-15", "completion_date": "2031-02-13", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06401330" }, { "nct_id": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR-Mutated Non-Small-Cell Lung Carcinoma", "Small Cell/Neuroendocrine" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-07", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538378" }, { "nct_id": "NCT03476174", "title": "Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ralph Hauke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-05-07", "completion_date": "2019-10-16", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03476174" }, { "nct_id": "NCT06833502", "title": "Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Node-positive Breast Cancer" ], "interventions": [ { "name": "CT Scan", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-02-24", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06833502" }, { "nct_id": "NCT03493945", "title": "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Neoplasm", "Advanced Solid Tumor", "Solid Tumor", "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" }, { "name": "MVA-BN-Brachyury", "type": "BIOLOGICAL" }, { "name": "FPV-Brachyury", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Benadryl", "type": "OTHER" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2018-05-01", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-11T16:17:27.570Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493945" } ] }